GlassScriptPhysician profile
Monique Torres
NPI 1093807653
$5,071.15
in general payments reported to CMS, 2019-2025
22 companies · $2,798 in 2025
The $2,798 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $178 · 2022: $313 · 2023: $927 · 2024: $855 · 2025: $2,798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,505 · Travel and Lodging: $1,747 · Education: $328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,505.04 |
| Travel and Lodging | $1,747.46 |
| Education | $327.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $1,997.52 | 2025 | |
| Janssen Biotech, INC. | $912.25 | 2023-2025 | Tremfya |
| Incyte Corporation | $340.75 | 2023-2025 | Opzelura |
| Abbvie INC. | $332.47 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.98 | 2022-2024 | Spevigo |
| E.R. Squibb & Sons, L.L.C. | $177.62 | 2023-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $161.65 | 2023-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $152.29 | 2022-2025 | |
| Amgen INC. | $140.10 | 2022-2025 | Otezla |
| Novo Nordisk INC | $135.51 | 2021-2023 | Ozempic, Rybelsus |
| Leo Pharma INC. | $76.41 | 2021-2025 | Anzupgo, Adbry |
| Novartis Pharmaceuticals Corporation | $75.05 | 2022-2024 | |
| Genzyme Corporation | $73.75 | 2024 | |
| Dermavant Sciences, INC. | $62.60 | 2023 | Vtama |
| Ucb, INC. | $55.67 | 2022-2024 | Bimzelx |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $45.00 | 2021 | |
| Almirall LLC | $42.94 | 2021-2022 | |
| Epi Health, LLC | $37.44 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $21.98 | 2022 | |
| Galderma Laboratories, L.P. | $18.47 | 2025 | Nemluvio |
| Lilly USA, LLC | $17.52 | 2025 | Kisunla |
| Sanofi-Aventis U.S. LLC | $11.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monique Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.